ADC Therapeutics SA (ADCT) reported a net loss for the quarter ended December 31, 2025, of $6.4 million, or a net loss of $0.04 per share, as compared to net loss of $30.7 million, or a net loss of $0.29 per share, prior year. Adjusted net loss was $13.5 million, or an adjusted net loss of $0.09 per share as compared to an adjusted net loss of $26.5 million, or $0.25 share, a year ago.
Net product revenues were $22.3 million for the fourth quarter as compared to $16.4 million for the same period in 2024.
In pre-market trading on NYSE, ADC shares are up 7.58 percent to $4.54.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.